BHPW
TEVA icon

Beverly Hills Private Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

Beverly Hills Private Wealth’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,657
Closed -$213K – 349
2024
Q4 		$213K Buy
+9,657
New +$176K 0.04% 312

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Beverly Hills Private Wealth's TEVA Position: Q1 2025 in Review

Beverly Hills Private Wealth sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 9,657 shares — an estimated $213K sold.

Beverly Hills Private Wealth first reported a position in TEVA in Q4 2024 and held it in 1 quarter. The position peaked at $213K in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Beverly Hills Private Wealth reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Beverly Hills Private Wealth sold 9,657 Teva Pharmaceuticals shares in Q1 2025, an estimated $213K.
  • Beverly Hills Private Wealth first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Beverly Hills Private Wealth's Teva Pharmaceuticals position peaked at $213K in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Beverly Hills Private Wealth's 13F filing for Q1 2025, filed 30 Apr 2025.